A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1-refractory merkel cell carcinoma.

被引：0
|
作者：
Shalhout, Sophia Z.
Emerick, Kevin S.
Kaufman, Howard E.
Miller, David M.
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Div Hematol Oncol, Dept Med, Boston, MA USA
[2] Harvard Med Sch, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, Boston, MA USA
[3] Massachusetts Gen Hosp, Dept Surg, Boston, MA USA
[4] Massachusetts Gen Hosp, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9521
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma
    Campbell, Katie M.
    Bustami, Zaid
    Chen, Daniel G.
    Medina, Egmidio
    Gonzalez, Cynthia R.
    Aldeen, Nataly Naser
    Baselga-Carretero, Ignacio
    Vega-Crespo, Agustin
    Maxey, Jessica
    Chen, Jia M.
    Kuklinski, Lawrence F.
    Kendra, Kari L.
    Chmielowski, Bartosz
    Thach-Giao Truong
    Khushalani, Nikhil I.
    Collichio, Frances
    Ikeguchi, Alexandra
    Victor, Adrienne I.
    Margolin, Kim
    Sosman, Jeffrey A.
    Patel, Sapna P.
    Hu-Lieskovan, Siwen
    Moon, James
    Bellasea, Shay
    Wells, Daniel K.
    Spencer, Christine N.
    Thompson, Marshall A.
    Wu, Michael
    Scumpia, Philip O.
    VanderWalde, Ari
    Ribas, Antoni
    CANCER RESEARCH, 2024, 84 (06)
  • [32] Durable responses to avelumab (anti-PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year efficacy update
    Kaufman, Howard L.
    Russell, Jeffery S.
    Hamid, Omid
    Bhatia, Shailender
    Terheyden, Patrick
    D'Angelo, Sandra P.
    Shih, Kent C.
    Lebbe, Celeste
    Milella, Michele
    Brownell, Isaac
    Lewis, Karl D.
    Lorch, Jochen H.
    von Heydebreck, Anja
    Mahnke, Lisa
    Nghiem, Paul
    CANCER RESEARCH, 2017, 77
  • [33] Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
    VanderWalde, Ari
    Bellasea, Shay L.
    Kendra, Kari L.
    Khushalani, Nikhil I.
    Campbell, Katie M.
    Scumpia, Philip O.
    Kuklinski, Lawrence F.
    Collichio, Frances
    Sosman, Jeffrey A.
    Ikeguchi, Alexandra
    Victor, Adrienne I.
    Truong, Thach-Giao
    Chmielowski, Bartosz
    Portnoy, David C.
    Chen, Yuanbin
    Margolin, Kim
    Bane, Charles
    Dasanu, Constantin A.
    Johnson, Douglas B.
    Eroglu, Zeynep
    Chandra, Sunandana
    Medina, Egmidio
    Gonzalez, Cynthia R.
    Baselga-Carretero, Ignacio
    Vega-Crespo, Agustin
    Garcilazo, Ivan Perez
    Sharon, Elad
    Hu-Lieskovan, Siwen
    Patel, Sapna P.
    Grossmann, Kenneth F.
    Moon, James
    Wu, Michael C.
    Ribas, Antoni
    NATURE MEDICINE, 2023, 29 (09) : 2278 - +
  • [34] PD-L1 in circulating exosomes of Merkel cell carcinoma
    Zanella, Anais
    Vautrot, Valentin
    Aubin, Francois
    Avoscan, Laure
    Samimi, Mahtab
    Garrido, Carmen
    Gobbo, Jessica
    Nardin, Charlee
    EXPERIMENTAL DERMATOLOGY, 2022, 31 (06) : 869 - 877
  • [35] Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
    Ari VanderWalde
    Shay L. Bellasea
    Kari L. Kendra
    Nikhil I. Khushalani
    Katie M. Campbell
    Philip O. Scumpia
    Lawrence F. Kuklinski
    Frances Collichio
    Jeffrey A. Sosman
    Alexandra Ikeguchi
    Adrienne I. Victor
    Thach-Giao Truong
    Bartosz Chmielowski
    David C. Portnoy
    Yuanbin Chen
    Kim Margolin
    Charles Bane
    Constantin A. Dasanu
    Douglas B. Johnson
    Zeynep Eroglu
    Sunandana Chandra
    Egmidio Medina
    Cynthia R. Gonzalez
    Ignacio Baselga-Carretero
    Agustin Vega-Crespo
    Ivan Perez Garcilazo
    Elad Sharon
    Siwen Hu-Lieskovan
    Sapna P. Patel
    Kenneth F. Grossmann
    James Moon
    Michael C. Wu
    Antoni Ribas
    Nature Medicine, 2023, 29 : 2278 - 2285
  • [36] Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors
    Hernandez-Prat, Anna
    Rodriguez-Vida, Alejo
    Cardona, Laura
    Qin, Mengjuan
    Arpi-Llucia, Oriol
    Soria-Jimenez, Luis
    Menendez, Silvia
    Quimis, Fabricio Gerel
    Galindo, Miguel
    Arriola, Edurne
    Salido, Marta
    Juanpere-Rodero, Nuria
    Rojo, Federico
    Muntasell, Aura
    Albanell, Joan
    Rovira, Ana
    Bellmunt, Joaquim
    MOLECULAR ONCOLOGY, 2025, 19 (01) : 151 - 172
  • [37] PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma
    Mitteldorf, Christina
    Berisha, Arbeneshe
    Tronnier, Michael
    Pfaltz, Monique C.
    Kempf, Werner
    JOURNAL OF CUTANEOUS PATHOLOGY, 2017, 44 (09) : 740 - 746
  • [38] Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
    Puccini, Alberto
    Battaglin, Francesca
    Iaia, Maria Laura
    Lenz, Heinz-Josef
    Salem, Mohamed E.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [39] Hair RepigmentationWith Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis
    Sebaratnam, Deshan Frank
    Rodriguez Bandera, Ana Isabel
    Lowe, Patricia Margaret
    JAMA DERMATOLOGY, 2018, 154 (01) : 112 - 113
  • [40] Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
    Swaika, Abhisek
    Hammond, William A.
    Joseph, Richard W.
    MOLECULAR IMMUNOLOGY, 2015, 67 (02) : 4 - 17
12345